Holen Sie sich die Stockscreener-App
90.08
0.44%
-0.40
Handel nachbörslich:
90.90
0.82
+0.91%
Schlusskurs vom Vortag:
$90.48
Offen:
$89.415
24-Stunden-Volumen:
962.29K
Relative Volume:
0.71
Marktkapitalisierung:
$7.39B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-153.72M
KGV:
-45.04
EPS:
-2
Netto-Cashflow:
$-103.81M
1W Leistung:
-5.29%
1M Leistung:
+7.11%
6M Leistung:
+86.89%
1J Leistung:
+482.66%
1-Tages-Spanne:
$89.10
$93.39
1-Wochen-Bereich:
$89.10
$97.44
52-Wochen-Spanne:
$15.15
$99.01
Verona Pharma Plc Adr Stock (VRNA) Company Profile
Firmenname
Verona Pharma Plc Adr
Sektor
Branche
Telefon
011-44-0-2032834200
Adresse
3 MORE LONDON RIVERSIDE, LONDON
Vergleichen Sie VRNA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRNA
Verona Pharma Plc Adr
|
90.08 | 7.39B | 0 | -153.72M | -103.81M | -2.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Verona Pharma Plc Adr Stock (VRNA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-28 | Eingeleitet | TD Cowen | Buy |
| 2025-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-01-10 | Eingeleitet | ROTH MKM | Buy |
| 2024-10-03 | Eingeleitet | Wells Fargo | Overweight |
| 2023-05-22 | Fortgesetzt | Jefferies | Buy |
| 2022-09-19 | Fortgesetzt | Wedbush | Outperform |
| 2022-08-26 | Eingeleitet | Piper Sandler | Overweight |
| 2021-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-08-25 | Eingeleitet | Jefferies | Buy |
| 2020-08-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-04-18 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Verona Pharma Plc Adr Aktie (VRNA) Neueste Nachrichten
Verona Pharma: A Blockbuster Franchise In The Making - Seeking Alpha
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today - Barchart.com
21 Best-Performing Small-Cap Stocks for June 2025 - NerdWallet
Regeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data - Benzinga
Verona Pharma ADR Surges, Matches Key 52-Week High: What’s Fueling the Rally? - Daily Chhattisgarh News
Verona Pharma stock soars to all-time high of $77.08 By Investing.com - Investing.com Nigeria
FDA Approves GSK's Nucala for Expanded Use in COPD - Zacks Investment Research
Restart of Student Loan Repayments Could Squeeze Consumer Spending and Slow Economic Growth - iHeart
Verona Pharma stock soars to all-time high of $74.36 By Investing.com - Investing.com UK
Market Update: Verona Pharma Plc ADR (VRNA) Sees Negative Movement, Closing at 69.14 - DWinneX
Verona Pharma Plc ADR (NASDAQ: VRNA): An Enticing Stock To Watch - Stocksregister
Verona Pharma’s general counsel sells shares worth $234,126 By Investing.com - Investing.com India
Verona Pharma director Vikas Sinha sells $178,416 in stock By Investing.com - Investing.com South Africa
Verona Pharma’s general counsel sells shares worth $234,126 - Investing.com
Verona Pharma Plc ADR (VRNA)’s Market Momentum: Closing Strong at 72.07, Down -1.56 - DWinneX
What is Verona Pharma Plc ADR (VRNA) Stock Return on Shareholders’ Capital? - Sete News
Verona Pharma Plc ADR [VRNA] Stock trading around $73.21 per share: What’s Next? - dbtnews.com
VRNA’s Stock Market Odyssey: A Year of Growth, Decline, and Resilience - investchronicle.com
Watch this stock’s price performance: Verona Pharma Plc ADR (NASDAQ:VRNA) - uspostnews.com
Verona Pharma ADR earnings beat by $0.05, revenue topped estimates - Investing.com UK
Verona Pharma Plc ADR (NASDAQ: VRNA) Could Soar To Much Higher Prices In Coming Months - Marketing Sentinel
TD Cowen starts Verona Pharma stock at Buy, sets $100 target - Investing.com
Verona Pharma Shareholders Approve All Proposals at AGM By Investing.com - Investing.com South Africa
Verona Pharma Shareholders Approve All Proposals at AGM - Investing.com
A significant driver of top-line growth: Verona Pharma Plc ADR (VRNA) - Sete News
Is Astrazeneca plc ADR (AZN) positioned for future growth? - Sete News
Verona Pharma Plc ADR [VRNA] Records 50-Day SMA of $62.73 - knoxdaily.com
Tencent Music Entertainment Group ADR [TME] Officer makes an insider purchase of 1,036,363 shares worth 14.87 million. – Knox Daily - knoxdaily.com
TAL Education Group ADR [TAL] Officer makes an insider purchase of 24,041 shares worth 0.28 million. - knoxdaily.com
Ratios Uncovered: Breaking Down Verona Pharma Plc ADR (VRNA)’s Trailing Twelve Months Metrics - DWinneX
Verona Pharma Plc ADR (VRNA) is a good investment, but the stock may be overvalued - uspostnews.com
What is the investor’s view on Marriott Vacations Worldwide Corp (VAC)? - uspostnews.com
Was Phathom Pharmaceuticals Inc (PHAT)’s session last reading good? - uspostnews.com
Zentalis Pharmaceuticals Inc (ZNTL) deserves deeper analysis - uspostnews.com
Financial Health Report: Alamos Gold Inc (AGI)’s Ratios Tell a Tale - DWinneX
Cantor Fitzgerald sets $80 target on Verona Pharma stock By Investing.com - Investing.com South Africa
Investing in Verona Pharma Plc ADR (VRNA) might be a great opportunity, but the stock is a bit undervalued - uspostnews.com
Verona Pharma Plc ADR [VRNA] Rickard Kathleen A. sells 79,264 Shares for $0.66 million - knoxdaily.com
Verona Pharma Plc ADR [VRNA] Chief Medical Officer makes an insider purchase of 79,264 shares worth 0.66 million. - knoxdaily.com
Verona Pharma secures $450 million credit facility on better terms By Investing.com - Investing.com South Africa
Verona Pharma secures $450 million credit facility on better terms - Investing.com
Xeris Biopharma reshuffles board, appoints new director - Investing.com
The growth track for Cracker Barrel Old Country Store Inc (CBRL) has changed recently - SETE News
Verona Pharma Plc ADR (NASDAQ: VRNA) Up 298.80% This Year: What Is Going To Happen Next - Stocks Register
Verona Pharma’s chief medical officer sells shares worth $661,941 - Investing.com India
Verona Pharma’s chief medical officer sells shares worth $661,941 By Investing.com - Investing.com South Africa
Keeping an Eye on Gilead Sciences, Inc (GILD) After Insider Trading Activity - Knox Daily
McEwen Mining Inc (MUX) Becoming More Attractive for Investors - Knox Daily
Morgan Stanley Upgrades Solaredge Technologies Inc (SEDG) to an Equal-weight from an Underweight - Knox Daily
Verona Pharma at Leerink Global Healthcare: Eutuvera’s Promising Launch By Investing.com - Investing.com UK
Earnings call transcript: Verona Pharma Q4 2024 beats EPS & revenue forecasts By Investing.com - Investing.com South Africa
Finanzdaten der Verona Pharma Plc Adr-Aktie (VRNA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Verona Pharma Plc Adr-Aktie (VRNA) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Fisher Andrew | General Counsel |
Jun 16 '25 |
Sale |
11.53 |
80,000 |
922,000 |
359,999 |
| Hahn Mark W | Chief Financial Officer |
Jun 11 '25 |
Sale |
11.40 |
400,000 |
4,560,360 |
12,278,992 |
| ZACCARDELLI DAVID | President and CEO |
Jun 11 '25 |
Sale |
11.40 |
400,000 |
4,560,520 |
13,190,168 |
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):